<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi> inhibits growth and invasive capacity of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells in vitro through its membrane (MT1 and MT2) and/or nuclear receptors (RORα) </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies showed that this indoleamine is present in both the <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> at similar levels </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we analyzed MT1, MT2, and RORα expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples versus <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa (NM) from patients suffering from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Given the existence of sex differences in the incidence and pathology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and the involvement of steroid receptors in the oncostatic actions of <z:chebi fb="9" ids="16796">melatonin</z:chebi> in some types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, we also analyzed the expression of <z:chebi fb="3" ids="50113">androgen</z:chebi> (AR) and <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor (ER) α and ERβ </plain></SENT>
<SENT sid="4" pm="."><plain>Finally, we conducted some experiments in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines to corroborate the experiments carried out in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We found a decreased expression of MT1, MT2, AR, ERα, and ERβ in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples versus NM, but no changes in RORα expression in the whole cohort of patients </plain></SENT>
<SENT sid="6" pm="."><plain>Classifying <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> by stage and gender, MT1, MT2, AR, ERα, and ERβ expression decreased in both early stage and advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, but only in male patients </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, MT1 and MT2 expression correlated positively with AR, ERα, and ERβ expression in male patients and with ERα or ERβ in female patients </plain></SENT>
<SENT sid="8" pm="."><plain>In vitro, the invasive capacity was higher in cells with the least expression of MT1, MT2, and AR, and nonselective MT1/MT2 <z:chebi fb="4" ids="48705">agonists</z:chebi> inhibited cell growth and invasion </plain></SENT>
<SENT sid="9" pm="."><plain>These results could indicate a possible interaction of these pathways </plain></SENT>
</text></document>